Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Partners with SeqGen for Service, Resale of GAIIx Sequencers


This article was originally published Oct. 21.

Illumina has signed on SeqGen as a third-party instrument service provider as well as a reseller for the Genome Analyzer IIx, SeqGen said last week.

Five of SeqGen's service engineers have recently been trained at Illumina to service the platform. The company now offers GAIIx instrument repair, decommissioning, installation, and training and assists in the sale of reconditioned GAIIx systems.

Torrance, Calif.-based SeqGen specializes in servicing DNA sequencers and refurbishing used sequencers for resale. The company was founded in 2000 by George Yang, previously the president of Azco Biosytems, another used sequencing instrument vendor (IS 3/25/2008).

According to its website, SeqGen offers a variety of refurbished Applied Biosystems capillary sequencers and has "provided service for many of the major genome centers and numerous university core facilities."

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.